<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03107091</url>
  </required_header>
  <id_info>
    <org_study_id>CIT-001</org_study_id>
    <nct_id>NCT03107091</nct_id>
  </id_info>
  <brief_title>Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites</brief_title>
  <official_title>Safety and Efficacy of Low-dose Terlipressin Delivered by Continuous Intravenous Infusion in Patients With Cirrhosis and Ascites Refractory to, or Intolerant of, Diuretic Therapy, Requiring Large Volume Paracentesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioVie Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioVie Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low-dose continuous infusion of terlipressin will be administered to six cirrhotic patients&#xD;
      with refractory ascites.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Terlipressin continuous infusion will be adminstered via an ambulatory pump initially for 7&#xD;
      days in a clinical pharmacology unit. Serial blood draws for pharmacokinetic analysis will be&#xD;
      performed to determine steady state concentration of both terlipressin and&#xD;
      8-lysine-vasopressin during infusion. After establishing safety and tolerance of infusion for&#xD;
      7 days, patients will be transitioned to an outpatient setting where they will be treated&#xD;
      with terlipressin continuous infusion for an additional 21 days, monitored daily by home care&#xD;
      nurses.&#xD;
&#xD;
      A total of 6 patients will be treated. Monitoring will include successful management of&#xD;
      ascites, with reduction in paracentesis procedures and decreased ascites fluid volume,&#xD;
      further supported by improvement in renal function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 15, 2017</start_date>
  <completion_date type="Actual">April 25, 2019</completion_date>
  <primary_completion_date type="Actual">April 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label prospective study in a cohort of 6 patients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Safety of Terlipressin Infusion in Cirrhotic Patients With Refractory Ascites</measure>
    <time_frame>28 day treatment period and 28 day post-treatment</time_frame>
    <description>Rate of treatment emergent adverse events assessed by physical examination and laboratory safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady State Plasma Levels of Terlipressin and 8-lysine Vasopressin During Terlipressin Continuous Infusion at 2 mg/Day in Cirrhotic Patients With Refractory Ascites</measure>
    <time_frame>7 day treatment</time_frame>
    <description>Serial sampling for determination of Terlipressin concentration and metabolite 8-lysine vasopressin in plasma at steady state (Css)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Requirement of Large Volume Paracentesis With Continuous Infusion of Terlipressin</measure>
    <time_frame>28 day post-treatment</time_frame>
    <description>Comparison of pre-treatment and post-treatment incidence of therapeutic paracentesis and change in volume of ascites removed</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Ascites Hepatic</condition>
  <arm_group>
    <arm_group_label>Terlipressin acetate continuous infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous infusion of terlipressin starting at 2 mg/day over 7 days in-house and if tolerated continue treatment in the ambulatory setting for 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin acetate continuous infusion</intervention_name>
    <description>Low-dose continuous infusion of Terlipressin administered via ambulatory pump over 28 days</description>
    <arm_group_label>Terlipressin acetate continuous infusion</arm_group_label>
    <other_name>Terlipressin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with cirrhosis and refractory ascites who required 3 or more large volume (4&#xD;
             liters and more) paracenteses in the previous 60 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ascites with causes other than cirrhosis such as nephrogenic ascites or malignant&#xD;
             ascites due to peritoneal carcinomatosis&#xD;
&#xD;
          -  Total bilirubin &gt; 5 mg/dL&#xD;
&#xD;
          -  Blood clotting International normalized ratio (INR) &gt; 2.5&#xD;
&#xD;
          -  Serum creatinine &gt; 2.0 mg/dL&#xD;
&#xD;
          -  Current or recent (within 3 months of consent) renal dialysis&#xD;
&#xD;
          -  Hepatic encephalopathy grade 3 or 4&#xD;
&#xD;
          -  Superimposed acute liver failure/injury due to factors other than alcoholic hepatitis,&#xD;
             including acute viral hepatitis, drugs, medications (e.g., acetaminophen), or other&#xD;
             toxins (e.g., mushroom [Amanita] poisoning)&#xD;
&#xD;
          -  Current or recent treatment (within 7 days) with octreotide, midodrine, vasopressin,&#xD;
             dopamine or other vasopressors&#xD;
&#xD;
          -  Respiratory failure requiring positive airway pressure devices or intubation&#xD;
&#xD;
          -  SIRS/sepsis episode in the previous 28 days from consent&#xD;
&#xD;
          -  Episode of spontaneous bacterial peritonitis or gastrointestinal hemorrhage within 28&#xD;
             days of consent&#xD;
&#xD;
          -  Ongoing documented or suspected infection&#xD;
&#xD;
          -  Severe cardiovascular disease that are contraindication to terlipressin therapy such&#xD;
             as advanced arteriosclerosis, arrhythmia, coronary insufficiency or uncontrolled&#xD;
             hypertension&#xD;
&#xD;
          -  Findings suggestive of organic renal disease (severe proteinuria/hematuria, or&#xD;
             abnormal renal ultrasound suggestive of obstructive or other renal pathology)&#xD;
&#xD;
          -  Severe comorbidity that in the opinion of the Investigator would affect short-term&#xD;
             prognosis and/or disallow safe participation in the trial (such as for example, severe&#xD;
             anemia or pancytopenia, advanced neoplasia, hepatocellular carcinoma [confirmed with&#xD;
             serum alpha1-fetoprotein testing], severe chronic obstructive pulmonary disease or&#xD;
             asthma)&#xD;
&#xD;
          -  Alcoholics who have not been abstinent for the past 6 months&#xD;
&#xD;
          -  Transjugular intrahepatic portosystemic shunt or other surgical shunt&#xD;
&#xD;
          -  For female patients: Confirmed pregnancy&#xD;
&#xD;
          -  Known allergy or hypersensitivity to terlipressin&#xD;
&#xD;
          -  Participation in other clinical research studies involving the evaluation of other&#xD;
             investigational drugs or devices within 30 days of consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Yeramian, MD</last_name>
    <role>Study Director</role>
    <affiliation>BioVie Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hunter Holmes McGuire VA Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>November 20, 2016</study_first_submitted>
  <study_first_submitted_qc>April 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <results_first_submitted>March 15, 2021</results_first_submitted>
  <results_first_submitted_qc>June 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2021</results_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Terlipressin</keyword>
  <keyword>Terlipressin acetate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terlipressin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT03107091/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Single site</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Terlipressin Acetate Continuous Infusion</title>
          <description>Continuous infusion of terlipressin starting at 2 mg/day over 7 days in-house and if tolerated continue treatment in the ambulatory setting for 21 days&#xD;
Terlipressin acetate continuous infusion: Low-dose continuous infusion of Terlipressin administered via ambulatory pump over 28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Terlipressin Acetate Continuous Infusion</title>
          <description>Continuous infusion of terlipressin starting at 2 mg/day over 7 days in-house and if tolerated continue treatment in the ambulatory setting for 21 days&#xD;
Terlipressin acetate continuous infusion: Low-dose continuous infusion of Terlipressin administered via ambulatory pump over 28 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="36" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MELD score</title>
          <description>The Model for End-Stage Liver Disease (MELD) is a scoring system for assessing the severity of chronic liver disease and uses the subject's values for total bilirubin, serum creatinine, and the international normalized ratio (INR) for prothrombin time to predict survival. MELD is calculated according to the following formula:&#xD;
MELD = 3.78×ln[serum bilirubin (mg/dL)] + 11.2×ln[INR] + 9.57×ln[serum creatinine (mg/dL)] + 6.43&#xD;
The possible scores range from 6 to 40. The higher the MELD score the more severe the disease state.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" lower_limit="9" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum creatinine</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.30" lower_limit="0.9" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Child-Pugh score</title>
          <description>The Pugh-Child score is determined by scoring five clinical measures of liver disease. A score of 1, 2, or 3 is given to each measure, with 3 being the most severe. The five clinical measures are: total bilirubin, serum albumin, INR, ascites and hepatic encephalopathy. The total score determines severity of disease with Class A being least severe (5-6), Class B more severe (7-9) and Class C most severe (10-15).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9" lower_limit="7" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Safety of Terlipressin Infusion in Cirrhotic Patients With Refractory Ascites</title>
        <description>Rate of treatment emergent adverse events assessed by physical examination and laboratory safety</description>
        <time_frame>28 day treatment period and 28 day post-treatment</time_frame>
        <population>Enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Terlipressin Acetate Continuous Infusion</title>
            <description>Continuous infusion of terlipressin</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Safety of Terlipressin Infusion in Cirrhotic Patients With Refractory Ascites</title>
          <description>Rate of treatment emergent adverse events assessed by physical examination and laboratory safety</description>
          <population>Enrolled</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to drug withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Steady State Plasma Levels of Terlipressin and 8-lysine Vasopressin During Terlipressin Continuous Infusion at 2 mg/Day in Cirrhotic Patients With Refractory Ascites</title>
        <description>Serial sampling for determination of Terlipressin concentration and metabolite 8-lysine vasopressin in plasma at steady state (Css)</description>
        <time_frame>7 day treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Terlipressin Acetate Continuous Infusion</title>
            <description>Continuous infusion of terlipressin starting at 2 mg/day over 7 days in-house and if tolerated continue treatment in the ambulatory setting for 21 days&#xD;
Terlipressin acetate continuous infusion: Low-dose continuous infusion of Terlipressin administered via ambulatory pump over 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Steady State Plasma Levels of Terlipressin and 8-lysine Vasopressin During Terlipressin Continuous Infusion at 2 mg/Day in Cirrhotic Patients With Refractory Ascites</title>
          <description>Serial sampling for determination of Terlipressin concentration and metabolite 8-lysine vasopressin in plasma at steady state (Css)</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Terlipressin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48" lower_limit="1.67" upper_limit="3.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8-lysine vasopressin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.089" lower_limit="0.07" upper_limit="0.138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Requirement of Large Volume Paracentesis With Continuous Infusion of Terlipressin</title>
        <description>Comparison of pre-treatment and post-treatment incidence of therapeutic paracentesis and change in volume of ascites removed</description>
        <time_frame>28 day post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Terlipressin Acetate Continuous Infusion</title>
            <description>Continuous infusion of terlipressin starting at 2 mg/day over 7 days in-house and if tolerated continue treatment in the ambulatory setting for 21 days&#xD;
Terlipressin acetate continuous infusion: Low-dose continuous infusion of Terlipressin administered via ambulatory pump over 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Requirement of Large Volume Paracentesis With Continuous Infusion of Terlipressin</title>
          <description>Comparison of pre-treatment and post-treatment incidence of therapeutic paracentesis and change in volume of ascites removed</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent change in volume ascites removed during 28d treatment period versus 28d pre-treatment period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-66.5" lower_limit="-100.0" upper_limit="-35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change in LVP interval during treatment versus before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" lower_limit="0" upper_limit="414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>56 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Terlipressin Acetate Continuous Infusion</title>
          <description>Continuous infusion of terlipressin starting at 2 mg/day over 7 days in-house and if tolerated continue treatment in the ambulatory setting for 21 days&#xD;
Terlipressin acetate continuous infusion: Low-dose continuous infusion of Terlipressin administered via ambulatory pump over 28 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ruptured umbilical hernia</sub_title>
                <description>Umbilical hernia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Partial bowel obstruction</sub_title>
                <description>Intestinal obstruction</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <description>Hepatic encephalopathy</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteremia</sub_title>
                <description>Bacteremia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>tachycardia</sub_title>
                <description>tachycardia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <description>diarrhea</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Energy increased</sub_title>
                <description>Increased energy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>decreased appetitie</sub_title>
                <description>Decrease in appetite</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <description>Hyponatremia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Penelope Markham</name_or_title>
      <organization>BioVie</organization>
      <phone>17035989972</phone>
      <email>pmarkham@biovieinc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

